Shares of Aura Biosciences (AURA) gained 7.9% on Sept. 12 after the company announced encouraging data from a phase II study evaluating its lead candidate, bel-sar (AU-011), to treat early-stage choroidal melanoma (CM) in the first-line setting. Bel-sar is a novel investigational agent designed with a dual mechanism of action that includes targeted cytotoxicity and immune activation.CM is a type of cancer occurring in the choroid, a layer of blood vessels and connective tissue between the sclera (white of t ...